Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Sanhuang Jingshiming Pills in neovascular age-related macular degeneration
CTR20254056Phase 3Active
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Oct 2025
- Countries
- 1
01
Overview
A Phase 3 trial of Sanhuang Jingshiming in exudative macular degeneration, sponsored by Tasly Pharmaceutical Group Co., Ltd.. Started Oct 2025; status: active.
02
Drugs
Sanhuang Jingshiming
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20254056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254056.